Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02208297 · ClinicalTrials.gov registry record · Phase 3
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT02208297 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 326 participants.
The verdict
NCT02208297, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)
Interventions
- DRUG Loteprednol Etabonate Gel (BID)
- DRUG Vehicle Gel (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02208297
The ClinicalTrials.gov registry entry for NCT02208297 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loteprednol Etabonate Gel (BID) is the first listed.
NCT02208297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02208297 about?
NCT02208297 is a clinical study titled "Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)
What is the current status of trial NCT02208297?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2014-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02208297?
The interventions under investigation include: Loteprednol Etabonate Gel (BID) (DRUG), Vehicle Gel (BID) (DRUG).
Who is sponsoring clinical trial NCT02208297?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.